1. Home
  2. ADNT vs BHVN Comparison

ADNT vs BHVN Comparison

Compare ADNT & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADNT
  • BHVN
  • Stock Information
  • Founded
  • ADNT 2016
  • BHVN 2013
  • Country
  • ADNT Ireland
  • BHVN United States
  • Employees
  • ADNT N/A
  • BHVN N/A
  • Industry
  • ADNT Auto Parts:O.E.M.
  • BHVN Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADNT Consumer Discretionary
  • BHVN Health Care
  • Exchange
  • ADNT Nasdaq
  • BHVN Nasdaq
  • Market Cap
  • ADNT 1.6B
  • BHVN 1.4B
  • IPO Year
  • ADNT N/A
  • BHVN 2017
  • Fundamental
  • Price
  • ADNT $22.74
  • BHVN $13.50
  • Analyst Decision
  • ADNT Hold
  • BHVN Strong Buy
  • Analyst Count
  • ADNT 9
  • BHVN 14
  • Target Price
  • ADNT $20.06
  • BHVN $58.85
  • AVG Volume (30 Days)
  • ADNT 1.2M
  • BHVN 1.6M
  • Earning Date
  • ADNT 08-06-2025
  • BHVN 08-07-2025
  • Dividend Yield
  • ADNT N/A
  • BHVN N/A
  • EPS Growth
  • ADNT N/A
  • BHVN N/A
  • EPS
  • ADNT N/A
  • BHVN N/A
  • Revenue
  • ADNT $14,384,000,000.00
  • BHVN N/A
  • Revenue This Year
  • ADNT N/A
  • BHVN $3.00
  • Revenue Next Year
  • ADNT N/A
  • BHVN $59.97
  • P/E Ratio
  • ADNT N/A
  • BHVN N/A
  • Revenue Growth
  • ADNT N/A
  • BHVN N/A
  • 52 Week Low
  • ADNT $10.04
  • BHVN $13.04
  • 52 Week High
  • ADNT $26.59
  • BHVN $55.70
  • Technical
  • Relative Strength Index (RSI)
  • ADNT 66.24
  • BHVN 42.74
  • Support Level
  • ADNT $21.58
  • BHVN $13.30
  • Resistance Level
  • ADNT $23.25
  • BHVN $14.09
  • Average True Range (ATR)
  • ADNT 0.71
  • BHVN 0.82
  • MACD
  • ADNT -0.16
  • BHVN 0.05
  • Stochastic Oscillator
  • ADNT 67.46
  • BHVN 19.74

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is the leading seating supplier to the industry with about one third of the global market. Its share in China is now nearly 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.8 billion in fiscal 2024 and consolidated China revenue was $1.4 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2024 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.7 billion but will likely be below $14 billion in fiscal 2025 on tariff interruptions and divesting some lower-quality business.

About BHVN Biohaven Ltd.

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Share on Social Networks: